Subtopic Deep Dive
Antiviral Therapy for HBV Infection
Research Guide
What is Antiviral Therapy for HBV Infection?
Antiviral therapy for HBV infection uses nucleos(t)ide analogs like lamivudine and entecavir alongside interferons to suppress viral replication, prevent resistance, and reduce risks of cirrhosis and hepatocellular carcinoma.
Nucleos(t)ide analogs achieve viral suppression in most patients but require indefinite treatment due to low functional cure rates. Long-term entecavir therapy significantly lowers HCC incidence compared to lamivudine, which faces high resistance from specific mutations (Hosaka et al., 2012; 700 citations). Over 10 key papers from 1995-2016 detail clinical trials, resistance mechanisms, and guidelines (Lok and McMahon, 2007; 3090 citations).
Why It Matters
Antiviral therapies prevent progression to cirrhosis and HCC, the leading cause of liver cancer deaths (Balogh et al., 2016; 1171 citations). Long-term entecavir reduces HCC risk in HBV patients (Hosaka et al., 2012). Lamivudine trials established nucleoside analog efficacy but highlighted resistance mutations like those identified by Allen et al. (1998; 801 citations), guiding modern resistance monitoring. Guidelines from Sarin et al. (2015; 2504 citations) optimize therapy to minimize renal and bone risks during prolonged suppression.
Key Research Challenges
Nucleoside Analog Resistance
Lamivudine resistance arises from specific HBV polymerase mutations, leading to viral breakthrough (Allen et al., 1998; 801 citations). This necessitates switching to potent agents like entecavir (Zoulim and Locarnini, 2009; 691 citations). Long-term monitoring is required to detect resistant variants early.
Achieving Functional Cure
Current therapies suppress HBV DNA but rarely eliminate cccDNA, preventing HBsAg loss (Seeger and Mason, 2015; 835 citations). No regimen achieves seroclearance in most patients (Lok and McMahon, 2007). Treatment cessation criteria remain undefined.
Long-term Safety Monitoring
Prolonged nucleos(t)ide use risks renal toxicity and bone density loss (Sarin et al., 2015). Trials show flare risks upon cessation (Hosaka et al., 2012). Balancing suppression benefits against adverse events challenges clinical management.
Essential Papers
Chronic hepatitis B
Anna S. Lok, Brian J. McMahon · 2007 · Hepatology · 3.1K citations
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Shiv Kumar Sarin, Manoj Kumar, George Lau et al. · 2015 · Hepatology International · 2.5K citations
Hepatocellular carcinoma: a review
Julius Balogh, David W. Victor, Emad H. Asham et al. · 2016 · Journal of Hepatocellular Carcinoma · 1.2K citations
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. In the United States, HCC is the ninth leading cause of cancer d...
Molecular biology of hepatitis B virus infection
Christoph Seeger, William S. Mason · 2015 · Virology · 835 citations
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection #
Cindy M. Weinbaum, Eric E. Mast, John W. Ward · 2009 · Hepatology · 817 citations
Abstract Early identification of persons with chronic HBV infection enables infected persons to receive necessary care to prevent or delay onset of liver disease, and enables the identification and...
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Jules L. Dienstag, Robert P. Perrillo, Eugene R. Schiff et al. · 1995 · New England Journal of Medicine · 809 citations
In a preliminary trial, 12 weeks of lamivudine therapy was well tolerated, and daily doses of 100 mg and 300 mg reduced HBV DNA to undetectable levels.
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
Marchelle I. Allen, Manon Deslauriers, William H. Andrews et al. · 1998 · Hepatology · 801 citations
Cirrhosis and hepatocellular carcinoma occur as long-term complications of chronic hepatitis B virus (HBV) infection. Antiviral therapy is potentially a successful approach for the treatment of pat...
Reading Guide
Foundational Papers
Start with Lok and McMahon (2007; 3090 citations) for therapy overview, then Dienstag et al. (1995; 809 citations) for lamivudine evidence, and Allen et al. (1998; 801 citations) for resistance basics.
Recent Advances
Study Hosaka et al. (2012; 700 citations) for entecavir long-term outcomes and Sarin et al. (2015; 2504 citations) for updated guidelines.
Core Methods
Nucleos(t)ide analogs target HBV polymerase for replication suppression; resistance sequencing identifies YMDD motif mutations; HCC risk assessed via long-term cohort studies.
How PapersFlow Helps You Research Antiviral Therapy for HBV Infection
Discover & Search
Research Agent uses searchPapers and citationGraph on 'entecavir HCC reduction' to map Hosaka et al. (2012) connections to 700+ citing works, then exaSearch uncovers resistance guidelines like Sarin et al. (2015), revealing 2504-citation impact.
Analyze & Verify
Analysis Agent applies readPaperContent to extract lamivudine trial data from Dienstag et al. (1995), verifies suppression claims via verifyResponse (CoVe) against Lok and McMahon (2007), and runs PythonAnalysis on resistance mutation frequencies with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in functional cure papers via contradiction flagging across Seeger and Mason (2015) and Zoulim and Locarnini (2009), then Writing Agent uses latexEditText, latexSyncCitations for Lok et al., and latexCompile to generate therapy review manuscripts with exportMermaid for resistance pathway diagrams.
Use Cases
"Analyze HBV DNA suppression rates from lamivudine vs entecavir trials using statistics"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Dienstag 1995, Hosaka 2012) → runPythonAnalysis (pandas t-test on extracted data) → statistical p-values and GRADE-verified comparison table.
"Draft LaTeX review on HBV resistance mutations with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText (resistance section) → latexSyncCitations (Allen 1998, Zoulim 2009) → latexCompile → formatted PDF with synced bibliography.
"Find code for HBV sequence analysis from resistance papers"
Research Agent → citationGraph (Allen 1998) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for mutation detection pipelines.
Automated Workflows
Deep Research workflow scans 50+ papers on nucleos(t)ide analogs via searchPapers → citationGraph → structured report on resistance evolution from Dienstag (1995) to Hosaka (2012). DeepScan applies 7-step CoVe analysis to verify HCC risk reduction claims in entecavir trials. Theorizer generates hypotheses on cessation criteria from guideline papers like Sarin (2015).
Frequently Asked Questions
What defines antiviral therapy for HBV?
Nucleos(t)ide analogs like lamivudine and entecavir suppress HBV replication; interferons provide immune modulation (Lok and McMahon, 2007).
What are main methods in HBV therapy?
Oral nucleos(t)ide analogs achieve undetectable HBV DNA in most patients; pegylated interferon offers finite treatment but lower response rates (Sarin et al., 2015).
What are key papers on HBV antivirals?
Lok and McMahon (2007; 3090 citations) for guidelines; Dienstag et al. (1995; 809 citations) for lamivudine trials; Hosaka et al. (2012; 700 citations) for entecavir HCC prevention.
What are open problems in HBV therapy?
Functional cure via cccDNA elimination remains elusive; resistance prevention and safe cessation criteria need definition (Seeger and Mason, 2015; Zoulim and Locarnini, 2009).
Research Hepatitis B Virus Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antiviral Therapy for HBV Infection with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hepatitis B Virus Studies Research Guide